ArticleBiosafety and health2022
Combination of chemistry and material science to overcome health problems.
Article in Biosafety and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma.Materials today. Bio · 2025Article
- Nanoparticles destabilizing the cell membranes triggered by NIR light for cancer imaging and photo-immunotherapy.Nature communications · 2024Article
- Encapsulation of Ru(II) Polypyridine Complexes for Tumor-Targeted Anticancer Therapy.BME frontiers · 2023Review
- Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic.Biosafety and health · 2022Review
- Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near Infrared II Fluorescent Polymer for Photodynamic-Immunotherapy to Break the Step-Reduction Delivery Dilemma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Advanced biosafety materials for prevention and theranostics of biosafety issues.Biosafety and health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its outbreak, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has strongly influenced the life of the general public around the world. Based on its fast spread and high mortality, there is a need for novel therapeutic treatments to overcome this global health crisis. While medicinal chemistry is focused on the development of highly selective and affine inhibitors toward a specific target enzyme, material science is focused on the development of nanomaterials for selective drug delivery. Based on the individual strengths, these disciplines could synergistically act together and help overcome the limitations of the respective approach. Herein, the combination of medicinal chemistry with material science to overcome health problems with the example of SARS-CoV-2 is critically discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.